Samer Eid, MBA

Director, Corporate Development

Professional Overview
Samer Eid is an accomplished corporate development executive with over 15 years of experience in the pharmaceutical industry. As the Director of Corporate Development at Merck, he plays a pivotal role in shaping the company's growth strategy through strategic acquisitions, partnerships, and licensing agreements.

Experience Summary

Current Role
As the Director of Corporate Development at Merck, Samer is responsible for identifying and evaluating strategic opportunities that align with the company's long-term objectives. He leads cross-functional teams in conducting thorough market analyses, financial valuations, and due diligence to ensure successful integration of acquired assets. Under his leadership, Merck has secured several transformative deals that have bolstered the company's product pipeline and strengthened its competitive position in the market.

Career Progression
Prior to his current role, Samer served as the Director of Business Development and Licensing at Merck, where he played a key role in negotiating and structuring complex licensing agreements with leading biopharmaceutical companies. Earlier in his career, he held the position of Program Team Leader at Merck, where he contributed to the successful progression of several drug candidates through the development pipeline.

Academic Background
Samer holds a Master of Business Administration (MBA) degree from the University of Pennsylvania's Wharton School, where he specialized in strategy and finance. He also completed a postdoctoral fellowship at the Scripps Research Institute, further enhancing his scientific expertise and research capabilities.

Areas of Expertise

• Strategic corporate development and M&A

• Pharmaceutical licensing and partnership negotiations

• Financial modeling and valuation

• Cross-functional team leadership and collaboration

• Pharmaceutical industry trends and market analysis

Professional Impact
During his tenure at Merck, Samer has successfully led the acquisition of several late-stage drug candidates, which have the potential to address unmet medical needs and drive significant revenue growth for the company. His ability to identify and evaluate strategic opportunities has been instrumental in positioning Merck as a leader in the pharmaceutical industry.

Conclusion
Samer Eid's extensive experience in corporate development, coupled with his strong leadership and financial acumen, make him a valuable asset to Merck. As the company continues to navigate the ever-evolving pharmaceutical landscape, Samer's strategic vision and execution capabilities will undoubtedly play a crucial role in driving Merck's long-term growth and innovation.